drugset / Trial / NCT05699070
Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects
Non-randomizedSequentialOpen-labelTreatment
Summary
An open-label phase 1 study to evaluate pharmacokinetic/pharmacodynamic drug-drug interactions and safety/tolerability of DWC202211 and DWC202212 compared to coadministration in healthy
Timeline
- Start
- 2023-02-15
- Primary completion
- 2023-04-24
- Completion
- 2023-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 100 mg | — |
| Subject | DWC202211 | Unknown | 100 mg | — |
| Subject | DWC202212 | Unknown | 5 mg | — |
| Subject | Rabeprazole | Small molecule | 5 mg | — |
Indications
No indication recorded.